Redemplo Generic: When Will Generic Plozasiran Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Redemplo Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? November 2039 About 13 years away Why then?
- Has the FDA approved a generic? Not yet None in the FDA’s records yet Why not yet?
- When does the last patent end? September 2038 5 patents listed with the FDA
- Can you buy a generic today? Not yet No company lists one for sale
Generic plozasiran is expected to be available in November 2039, about 13 years away. None is for sale yet.
Why November 2039?
It is when Redemplo’s patents 10,597,657 and 11,214,801 end. They cover the active ingredient, the product’s formulation and a way of using it, and once they end, generics can go on sale as soon as the FDA approves them. It is too early to rate how firm that is.
Why hasn’t the FDA approved a generic yet?
That is normal before a launch. The FDA usually can’t give a generic its final approval while a patent or exclusivity still blocks it, so final approval often comes close to the day the generic can be sold. No company holds a “tentative” approval yet either (the FDA’s word for a generic that is ready but still blocked).
Will the generic cost less?
Usually, but no company is recorded as having applied to make one yet, and a single company usually brings only a modest drop. See the price pattern
What should I do now?
Keep taking Redemplo as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Redemplo by the Numbers
- Reason
- Patent expiresA patent that protects the brand runs out. After that, approved generics can be sold.
- How sure
- Not rated Too early to rate. The month is where the records point today.
- Price competition
- None filed yet No filers on record
- Brand sales
- Sales not reported
- FDA approved 2025 November 2025 FDA Orange Book
- Patents listed 5 last runs to September 2038 FDA Orange Book
- Medicare Part D spent $411.8K in January to March 2026, for 27 people CMS Part D Spending by Drug
Redemplo’s Road to a Generic
Redemplo has had the market to itself since the FDA approved it in November 2025 (Arrowhead Pharmaceuticals Inc). Its FDA protection (orphan drug) runs to November 2032. Its 5 listed patents run to September 2038.
The first generic of Redemplo is expected in November 2039.
Why that month: patents 10,597,657 and 11,214,801, on the active ingredient, the product’s formulation and a way of using it, end then.
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Redemplo Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Redemplo’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
The one that matters for a generic launch: patents 10,597,657 and 11,214,801, which end in September 2038; the first generic is expected after it, in November 2039, about 13 years away.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 10,294,474 | The active ingredient; the product’s formulation; a way of using it (U-4360) | March 2037 | Active |
| 11,174,481 | The active ingredient; the product’s formulation | March 2037 | Active |
| 10,597,657 Sets the expected month of generic availability | The active ingredient; the product’s formulation; a way of using it (U-4360) | September 2038 | Active |
| 11,214,801 Sets the expected month of generic availability | The active ingredient; the product’s formulation; a way of using it (U-4360) | September 2038 | Active |
| 12,365,899 | The active ingredient; the product’s formulation; a way of using it (U-4360) | September 2038 | Active |
| Exclusivity | What it means | Ends | Status |
|---|---|---|---|
| Orphan drug ODE-541 | Seven years of protection for a use in a rare disease. | November 2032 | Active |
Source: FDA Orange Book, application 219947. Patent numbers open the patent on Google Patents.
Who Is Lined Up to Make Generic Plozasiran
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
No company is recorded as having applied to the FDA to make a generic Redemplo yet.
Approved by the FDA
Not yet. The FDA has not approved a generic plozasiran. Final approval often comes close to the day a generic can be sold.
For Sale in Pharmacies
Not yet. No company lists a generic plozasiran for sale with the FDA.
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Redemplo Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Redemplo, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Redemplo
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Redemplo, before manufacturer rebates.
- $411.8K
- January to March 2026, the latest CMS has posted
For 27 people, about $15,252 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| January to March 2026 | $411,799 | 27 | $15,251.80 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Redemplo only, so no generic is counted in it. What CMS says it is used for: This medication is used along with a proper diet to help lower fats (triglycerides) in the blood. It is used by people who have a certain inherited condition (familial chylomicronemia syndrome) that causes high levels of triglycerides in the blood.
Redemplo Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML) | Solution | Subcutaneous | November 2025 | Prescription reference product |
Source: FDA Orange Book, Arrowhead Pharmaceuticals Inc. Listed for sale today by Arrowhead Pharmaceuticals, Inc. (FDA NDC Directory).
Redemplo NDC Codes and Packages
Each Redemplo package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 84141-0025-01 | PLOZASIRAN 25 mg/.5mL injection, solution | syringe of 1 mL | Arrowhead Pharmaceuticals, Inc. |
Source: the FDA NDC Directory, current listings only. Only packages sold under Redemplo’s own FDA approval (NDA 219947) are listed, never a generic. Some codes belong to companies that repackage Redemplo: it is the same medicine in a different package.
What a Generic Redemplo Means for You
Nothing Changes Until It Is in Pharmacies
Until a generic is actually for sale, keep filling Redemplo as usual. When one arrives, there is nothing you need to sign up for.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Redemplo”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.
Questions people ask about Redemplo
Is there a generic for Redemplo right now?
No. As of October 9, 2026 no generic plozasiran is listed for sale in the FDA NDC Directory.
When will Redemplo go generic?
November 2039 is the expected month. It is when Redemplo’s patents 10,597,657 and 11,214,801 end. They cover the active ingredient, the product’s formulation and a way of using it, and once they end, generics can go on sale as soon as the FDA approves them.
Will generic plozasiran be the same as Redemplo?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. No company is recorded as having applied to the FDA to make one yet, and a single company usually brings only a modest drop.
Has the FDA approved a generic Redemplo?
Not yet. The FDA Orange Book lists no approved generic version of Redemplo.
When does the Redemplo patent expire?
The FDA Orange Book lists 5 patents for Redemplo; the last runs to September 2038. The one behind the expected month is patents 10,597,657 and 11,214,801, which end in September 2038. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected month on this page (November 2039) weighs all of that.
Changes to This Projection
- First generic expected November 2039 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- XareltoRivaroxabanMarch 2027
- ErivedgeVismodegibNovember to December 2028
- KisqaliRibociclib SuccinateJuly to September 2031
- OrserduElacestrant Hydrochloride2035 to 2037
- AzstarysDexmethylphenidate Hydrochloride and Serdexmethylphenidate ChlorideDecember 2037
- SuprenzaPhentermine HydrochlorideTBD no date yet
About Redemplo
- Generic name plozasiran
- How it is taken Injection under the skin
- Company Arrowhead Pharmaceuticals Inc
- Hard to copy Inhalers, injectables, patches and other hard-to-copy products. Fewer companies attempt them and dates slip more often.
- More drugs Brand-name drugs starting with R
- Have a question? A pharmacist answers, free. Ask about Redemplo
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, CMS Medicare Part D Spending by Drug, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.